

Preclinical investigation of ADCT-242, a novel exatecan-based antibody drug conjugate targeting Claudin-6, as single agent or in combination in ovarian and non-small cell lung cancer models

Nicola Tsang*, Elizabeth Horsley, Narinder Janghra, Chris Pickford, Lolke de Haan & Patrick H. van Berkel

ADC Therapeutics, London UK



* Dr Tsang was an employee of ADCT when the study was conducted



Disclosure Information

APRIL 25-30 | AACR.ORG/AACR2025 | #AACR25

Chris Pickford PhD


I have the following relevant financial relationships to disclose:

Employee of ADC Therapeutics Stockholder in ADC Therapeutics

Claudin-6: A Promising ADC Target




APRIL 25-30 | AACR.ORG/AACR2025 | #AACR25




- → Member of the CLDN family of proteins
- → 23.3 kDa transmembrane protein with cytoplasmic C- and N-terminus
- → Involved in tight junctions, regulating cell adhesion, maintaining tissue integrity
- → Promotes cell proliferation, migration, invasion abilities and inhibits apoptosis
- → Implicated in the initiation, progression and metastasis of some cancers
- → Can be associated with poor prognosis in endometrial carcinoma
- \rightarrow Very restricted normal tissue expression

Clinical Rationale & Prevalence



→ TORL-1-23/ixotatug vedotin (DAR 4 MMAE): 50%/42% ORR at 2.4/3.0 mg/kg in Pt-resistant ovarian cancer




M+H refers to percent of cases with H-score ≥100. Source: Kojima et al., Cancer (2020); Fierce Biotech; STAT news; Du et al., Mol Med Rep (2021); Cao et al., Onco Targets Ther (2018); ADC Therapeutics Internal Studies.


ADCT-242: A Claudin-6 targeting ADC delivering an exatecan payload with best-in-class potential

AACR American Association for Cancer Research

APRIL 25-30 | AACR.ORG/AACR2025 | #AACR25




 ADCT-242 is comprised of a CLDN6-specific, humanized and Fcsilenced IgG1 antibody to which 6 exatecan-containing PL2202 payloads have been conjugated (DAR 6)




ADCT-242 shows superior in vitro internalisation properties to AB3-7-MMAE and strong bystander activity



APRIL 25-30 | AACR.ORG/AACR2025 | #AACR25



Primary Cytotoxicity



518,196

70,318


Isotype Ctrl ADC


Bystander Activity ADCT-242 $PA-1 \rightarrow KB$ CLDN6⁺ → CLDN6⁻ ival 100 Su Cell 50 % 150 $KB \rightarrow KB$ Isotype Ctrl ADC CLDN6⁻ → CLDN6⁻ Survival Cell 50. % 10³ 105 10-3 10-1 101 107 Concentration (pM) EC₅₀ (pM), EC₅₀ (pM) from PA-1 ADCT-242 142 124,938 Isotype Ctrl ADC 25,337 38,699

ADCT-242 has potent anti-tumor activity in vivo in xenograft models of ovarian cancer with medium CLDN6 expression



APRIL 25-30 | AACR.ORG/AACR2025 | #AACR25






Treatment	Regimen	PR	CR	TFS
2 mg/kg ADCT-242	QD×1	0/8	6/8	5/8
2 mg/kg Isotype Ctrl-PL2202	QD×1	0/8	0/8	0/8
2.5 mg/kg AB3-7-MMAE	QW×3	1/8	0/8	0/8
2.5 mg/kg Isotype Ctrl-MMAE	QW×3	0/8	0/8	0/8

PR=partial response; CR=complete response; TFS=tumor-free survivors


Claudin-6 dependent anti-tumour activity of ADCT-242 is observed in lung patient-derived xenograft models






In vitro combination studies demonstrate synergy of ADCT-242 with Olaparib across multiple cancer cell lines





Suboptimal doses of ADCT-242 and Cisplatin combine to drive complete tumour regression in the OVCAR-3 xenograft model






- Sub-optimal doses of ADCT-242 and Cisplatin combine to show strong synergy in vivo
- Single dose combination leads to 8/10 CR and 7/10 TFS in the OVCAR-3 xenograft model

ADCT-242 drives strong tumour growth inhibition of the OVCAR-3 xenograft *in vivo* model following treatment with a Claudin-6 targeting MMAE-based ADC (AB3-7-MMAE)






- ADCT-242 and AB3-7-MMAE dosed in combination show antagonistic activity in vivo
- Sequential treatment of AB3-7-MMAE followed by ADCT-242 shows strong tumour growth reduction

ADCT-242 was tolerated at doses up to 150 mg/kg in mice or 40 mg/kg in cynomolgus monkeys, indicative of a good therapeutic index




APRIL 25-30 | AACR.ORG/AACR2025 | #AACR25



Species	Dose Q3W×2	Tolerated	Clinical Pathology & Histopathology		
ج	75 mg/kg 150 mg/kg	Yes Yes	Clinical pathology: increases in RDW, RET and PLT; increases in ALP Histopathology: germ cell degeneration & tubular atrophy in the testes, increased spleen cellularity		
	20/30 mg/kg 40 mg/kg 60 mg/kg	Yes Yes No	Clinical Pathology: reductions in red cell parameters; reversible reductions in RET, WBC & subpopulations Histopathology: no findings up to 40 mg/kg; GI tract lesions dose limiting at 60 mg/kg		

Tolerability of ADCT-242 in mice and cynomolgus monkeys

ADCT-242 exhibits favourable exposure profile in cynomolgus monkeys



- → Mice & cynomolgus monkeys were considered pharmacologically relevant species based on CLDN6 binding
- → ADCT-242 Q3W×2 was well tolerated at doses up to 150 and 40 mg/kg, resp.
- → Favourable PK profile with $t_{\frac{1}{2}}$ of 9.7-12.6 and 8.5-10 days in mice and monkeys, resp.

RDW = red cell distribution width; *RET* = reticulocytes; *PLT* = platelets; *ALP* = alkaline phosphatase; *WBC* = white blood cells



Conclusions

- ADCT-242 is a Claudin-6 targeting ADC delivering an exatecan payload with best-in-class potential.
- ADCT-242 has potent anti-tumor activity in vivo in PA-1 and OVCAR-3 xenograft models of ovarian cancer with medium CLDN6 expression levels.
- Claudin-6 dependent anti-tumour activity of ADCT-242 is observed in lung patient-derived tumour models.
- In vitro combination studies demonstrate synergy of ADCT-242 with Olaparib across multiple cancer cell lines.
- Suboptimal doses of ADCT-242 and Cisplatin combine to drive complete tumour regression in the OVCAR-3 xenograft model demonstrating strong synergy *in vivo*.
- ADCT-242 drives strong tumour growth inhibition of the OVCAR-3 xenograft in vivo model following treatment with a Claudin-6 targeted MMAE-based ADC.
- ADCT-242 was tolerated at doses up to 150 mg/kg in mice or 40 mg/kg in cynomolgus monkeys, indicative of a good therapeutic index.



APRIL 25-30 | AACR.ORG/AACR2025 | #AACR25

Acknowledgements

ADCT – London



Patrick van Berkel, CSO

Protein Chemistry

Chris Gallagher Cecile Oblette Banusha Rajeenthira Nicole Bledowski

Medicinal Chemistry Paul Hogg Nicolas Veillard

Bioconjugation

Lisa Skelton Matthew Bird Alina Chryzastek Becky Martin Lea Rochet

Cancer Biology

Nicola Tsang* Danilo Cucchi Nari Janghra Asma Jabeen Chris Pickford Kristina Zaitseva

Bioanalytical Sciences

Charlie Britten Ben Leatherdale Simone Sims

Toxicology & PK Lolke de Haan Lina Baxter Liz Horsley

Copies of this presentation obtained through the Quick Response (QR) Code are for personal use only and may not be reproduced without the permission from the author of this presentation



* Dr Tsang was an employee of ADCT when the study was conducted